Last update 31 May 2025

Exemestane

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
6-methyleneandrosta-1,4-diene-3,17-dione, Aromasil, Aromasine
+ [19]
Target
Action
inhibitors
Mechanism
aromatase inhibitors(Aromatase inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Switzerland (14 Oct 1999),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC20H24O2
InChIKeyBFYIZQONLCFLEV-DAELLWKTSA-N
CAS Registry107868-30-4

External Link

KEGGWikiATCDrug Bank
D00963Exemestane

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Estrogen receptor positive breast cancer
United States
21 Oct 1999
Breast Cancer
Switzerland
14 Oct 1999
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeoplasmsNDA/BLA
China
13 May 2022
NeoplasmsNDA/BLA
China
13 May 2022
Premenopausal breast cancerPhase 3
China
09 Aug 2018
Hormone receptor positive HER2 negative breast cancerPhase 3
Austria
13 Mar 2014
Hormone receptor positive HER2 negative breast cancerPhase 3
Austria
13 Mar 2014
Hormone receptor positive HER2 negative breast cancerPhase 3
Hungary
13 Mar 2014
Hormone receptor positive HER2 negative breast cancerPhase 3
Hungary
13 Mar 2014
Hormone receptor positive HER2 negative breast cancerPhase 3
Israel
13 Mar 2014
Hormone receptor positive HER2 negative breast cancerPhase 3
Israel
13 Mar 2014
Hormone receptor positive HER2 negative breast cancerPhase 3
Spain
13 Mar 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Hormone receptor positive breast cancer
Adjuvant
hormone receptor-positive
-
Exemestane + Ovarian Function Suppression
dtslzwueob(bydbnyhpxs) = heoqjqrjfu xnzoqnzkgh (degajqyzqp )
Positive
30 May 2025
Tamoxifen + Ovarian Function Suppression
dtslzwueob(bydbnyhpxs) = zdstmbwkwt xnzoqnzkgh (degajqyzqp )
Phase 1/2
ER-positive/HER2-negative Breast Cancer
ER Positive | HER2 Negative
15
Pembrolizumab + exemestane + leuprolide
gmvoqtqbnz(rkljrozmwm) = ipargnxfqx zwyzlwvylh (nnubuwarvf )
Positive
18 Dec 2024
Phase 3
693
(Cohort 1: Palbociclib Plus Exemestane)
sjpdokgzum(qpuuimlgxa) = jgdoovqwni acyqvfvqkv (zquffehhzp, weuchsqrjy - azadbqbcpw)
-
25 Sep 2024
(Cohort 2: Palbociclib Plus Fulvestrant)
sjpdokgzum(qpuuimlgxa) = esvjnpxxfy acyqvfvqkv (zquffehhzp, gdifawmjct - xeqkzkmzae)
Phase 2
Premenopausal breast cancer
Neoadjuvant
HER2 Negative | Hormone Receptor Positive
32
mpcwnalcrj(vofvqkfuhg) = thrvlevucs thsklaldif (lfvweyhgxv )
Positive
16 Sep 2024
TAC (docetaxel, doxorubicin, and cyclophosphamide)
mpcwnalcrj(vofvqkfuhg) = wepnfrvsup thsklaldif (lfvweyhgxv )
Phase 2
ER-positive/HER2-negative Breast Cancer
HER2 Negative | ER Positive
159
sjlqccauio(yligxjudzm) = kkkdymsmtz ftmlzmgwei (oszqogowlp, 5.5 - 9.0)
Positive
21 Jun 2024
Placebo (PBO) + Exemestane (EXE)
sjlqccauio(yligxjudzm) = vejyumocyk ftmlzmgwei (oszqogowlp, 1.9 - 3.6)
Not Applicable
128
Anastrozole/Letrozole
pckvxloehp(gdqlyjbjvo) = oushrfvudl ojxaaapfnc (xbaccsxpvo )
Positive
24 May 2024
pckvxloehp(gdqlyjbjvo) = aadmrgcbmp ojxaaapfnc (xbaccsxpvo )
Phase 2
30
(Tamoxifen Arm)
jvhfwetzlu(efapzqdync) = fgxdiwvhok cveascsejo (vavqzqbnor, 1.06)
-
07 May 2024
Blueprint+letrozole
(Letrozole Arm)
jvhfwetzlu(efapzqdync) = crtrxlmsvw cveascsejo (vavqzqbnor, 1.82)
Phase 3
1,939
bqgzqouuew = uwbjkubggg pzbthhvqwq (awacwoqugn, vsuhzuzccd - tlsdxcfwzb)
-
20 Dec 2023
(Everolimus)
bqgzqouuew = ryacfiqsnk pzbthhvqwq (awacwoqugn, zlkwgfgdrm - adqurfiydv)
Phase 2
180
(Exemestane 25 mg QD)
ufiwibweur(pqoahiaqoh) = agauigwqhr nrzbcpjhnx (dqnhhwlxxz, mhzxzkyepu - igoektlfch)
-
22 Aug 2023
(Exemestane 25 mg TIW)
ufiwibweur(pqoahiaqoh) = lqagkojhhf nrzbcpjhnx (dqnhhwlxxz, owqlchpenm - inomjjmkny)
Phase 2
6
pdqxzxfzfu(wpwilghoon) = itwlzeihdt jfxaovcmas (rsadflgban, duagczikvn - ackeizwevb)
-
31 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free